Ralivia approval bolsters Biovail after disappointing second quarter
This article was originally published in Scrip
Executive Summary
Biovailhas received an expanded indication from the Therapeutic Products Directorate in Canada for its once-daily pain medication Ralivia (tramadol HCl) to include the treatment of moderately severe pain in addition to moderate pain. Ralivia is now indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more.